ESTRO-EANO guideline on target delineation and radiotherapy for IDHmutant WHO CNS grade 2 and 3 diffuse glioma.

Anaplastic glioma Consensus Delineation Diffuse glioma EANO ESTRO IDH mutant diffuse glioma Low grade glioma Proton therapy Radiotherapy Target volume

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
23 Oct 2024
Historique:
received: 10 10 2024
accepted: 12 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: aheadofprint

Résumé

This guideline will discuss radiotherapeutic management of IDH mutant grade 2 and grade 3 diffuse glioma, using the latest 2021 WHO (5th) classification of brain tumours focusing on: imaging modalities, tumour volume delineation, irradiation dose and fractionation. The ESTRO Guidelines Committee, CNS subgroup, nominated 15 European experts who identified questions for this guideline. Four working groups were established addressing specific questions concerning imaging, target volume delineation, radiation techniques and fractionation. A literature search was performed, and available literature was discussed. A modified two-step Delphi process was used with majority voting resulted in a decision or highlighting areas of uncertainty. Key issues identified and discussed included imaging needed to define target definition, target delineation and the size of margins, and technical aspects of treatment including different planning techniques such as proton therapy. The GTV should include any residual tumour volume after surgery, as well as the resection cavity. Enhancing lesions on T1 imaging should be included if they are indicative of residual tumour. In grade 2 tumours, T2/FLAIR abnormalities should be included in the GTV. In grade 3 tumours, T2/FLAIR abnormalities should also be included, except areas that are considered to be oedema which should be omitted from the GTV. A GTV to CTV expansion of 10 mm is recommended in grade 2 tumours and 15 mm in grade 3 tumours. A treatment dose of 50.4 Gy in 28 fractions is recommended in grade 2 tumours and 59.4 Gy in 33 fractions in grade 3 tumours. Radiation techniques with IMRT are the preferred approach.

Identifiants

pubmed: 39454886
pii: S0167-8140(24)03572-2
doi: 10.1016/j.radonc.2024.110594
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110594

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Brigitta G Baumert (BG)

Institute of Radiation-Oncology, Cantonal Hospital Graubunden, Chur, Switzerland. Electronic address: cgasparotto@estro.org.

Jaap P M Jaspers (J)

Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands.

Vera C Keil (VC)

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.

Norbert Galldiks (N)

Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine (IMN-3), Research Center Juelich, Juelich, Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.

Ewa Izycka-Swieszewska (E)

Department of Pathology and Neuropathology, Medical University of Gdansk, Gdansk, Poland.

Beate Timmermann (B)

West German Proton Therapy Centre Essen (WPE), University Hospital Essen, Essen, Germany; Department of Particle Therapy, University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Essen, Germany.

Anca L Grosu (AL)

Department of Radiation Oncology, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany.

Giuseppe Minniti (G)

Radiation Oncology Unit, Department of Radiological Sciences, Sapienza University of Rome, Rome, Italy.

Umberto Ricardi (U)

Department of Oncology, University of Turin, Turin, Italy.

Frédéric Dhermain (F)

Radiation Oncology Department, Gustave Roussy University Hospital, Villejuif, France.

Damien C Weber (DC)

Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, Villingen, Switzerland.

Martin van den Bent (M)

The Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

Roberta Rudà (R)

Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.

Maximilian Niyazi (M)

Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Tübingen, Germany; Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.

Sara Erridge (S)

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

Classifications MeSH